Previous close | 74.12 |
Open | 76.08 |
Bid | 73.91 x 100 |
Ask | 74.08 x 100 |
Day's range | 73.89 - 78.79 |
52-week range | 36.42 - 99.63 |
Volume | |
Avg. volume | 635,537 |
Market cap | 2.419B |
Beta (5Y monthly) | 2.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.77 |
Earnings date | 29 Apr 2024 - 03 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 100.50 |
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on March 15, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,418 shares of its common stock and an aggregate of 6,149 restricted stock units to 5 employees, each as a material inducement for each employee's entry into employment with TransMedics. The g
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
TransMedics Group Inc (NASDAQ:TMDX) CFO Stephen Gordon sold 15,000 shares of the company's stock on March 4, 2024, according to a recent SEC filing.